Infant of 22 months of age with no anomalies born from a HCV- and HIV-infected mother under treatment with pegylated interferon, ribavirin and antiretroviral therapy during the first 16 weeks of pregnancy.

The product label of ribavirin states that it is contraindicated during pregnancy, so the risk in its administering during pregnancy is concerned. We show a case of an infant of 22 months of age with no anomalies born from an HCV- and HIV-infected mother under treatment with pegylated interferon, ribavirin and antiretroviral therapy during the first 16 weeks of pregnancy. The infant is neither HIV- nor HCV-infected.